Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) will host a conference call at 5:00 p.m. ET on Tuesday, August 4, 2026, to discuss its financial results for the quarter ending June 30, 2026, and provide a corporate update. The biopharmaceutical company, focused on developing novel products for serious rare and ultra-rare genetic diseases, aims to share key performance metrics and strategic developments with investors during the event.

The live webcast of the conference call will be available through Ultragenyx’s investor relations website at https://ir.ultragenyx.com/events-presentations . A replay of the call will remain accessible for three months following the event, allowing stakeholders who cannot attend live to review the management discussion and analysis.

Event Details

Ultragenyx continues to advance its portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical needs. The company’s strategy emphasizes time- and cost-efficient drug development, targeting conditions where there are typically no approved therapies treating the underlying disease.

Management will likely address the commercialization progress of its existing products and the development status of its pipeline during the corporate update portion of the call. Investors should monitor the webcast for any updates on clinical trial milestones or regulatory filings that could impact the company’s near-term outlook.

For further information, investors can contact Joshua Higa at ir@ultragenyx.com , while media inquiries should be directed to Jess Rowlands at media@ultragenyx.com .

Johnson Fistel, PLLP is investigating potential claims on behalf of long-term shareholders of Ultragenyx Pharmaceutical Inc. against certain officers and directors for alleged breaches of fiduciary duty. The investigation centers on accusations that the company made materially false and misleading statements regarding its drug setrusumab and the Phase III ORBIT study in patients with osteogenesis imperfecta. Shareholders who have held shares continuously since prior to August 3, 2023, may have standing to seek corporate governance reforms, the return of funds to the company, and a court-approved incentive award.

A previously filed securities class action complaint alleges that Ultragenyx created a false impression that it possessed reliable information concerning the effects of setrusumab while minimizing the risk that the ORBIT study would fail to achieve a statistically significant reduction in annualized fracture rate. The complaint further claims that the company's optimism regarding the ORBIT study and its interim analysis benchmark was misplaced because the threshold figures were based on Phase II results that lacked a placebo control group for appropriate comparison. Consequently, the defendants' positive statements concerning Ultragenyx's business, operations, and prospects were allegedly materially misleading and lacked a reasonable basis.

Key Investigation Details

The investigation focuses on the period prior to August 3, 2023, and specifically addresses the following allegations:

• False Statements: Ultragenyx and its executives allegedly made materially false and misleading statements or failed to disclose material adverse facts.
• Study Risks: The company allegedly minimized the risk of failure for the ORBIT study to achieve a statistically significant reduction in annualized fracture rate.
• Data Reliability: The threshold figures for the study's interim analysis benchmark were allegedly based on Phase II results that lacked a placebo control group.

Shareholder Options

Affected shareholders may seek corporate governance reforms at Ultragenyx, including improvements to internal controls, transparency, and executive oversight. There is no cost or obligation to participate in the investigation. Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits.